Elagolix dosing regimens for GnRH receptor antagonists
Summary
USPTO published patent application US20260091036A1 for dosing regimens of Elagolix (a GnRH receptor antagonist) and related compounds. The application claims methods to minimize bone mineral density changes in subjects suffering from endometriosis, adenomyosis, PCOS, or uterine fibroids. Filing date August 26, 2025.
What changed
The patent application covers dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A/Elagolix) or salts thereof. The regimens are designed to treat reproductive health conditions while minimizing bone mineral density changes associated with GnRH receptor antagonists.
Pharmaceutical companies developing GnRH antagonists or treating related conditions should monitor this patent application. Competitors in the endometriosis, adenomyosis, PCOS, and uterine fibroids treatment spaces should review freedom-to-operate implications. No immediate compliance action required as this is a pending application.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Dosing Regimens for Elagolix
Application US20260091036A1 Kind: A1 Apr 02, 2026
Inventors
Mohamad Shebley
Abstract
The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.
CPC Classifications
A61K 31/513 A61K 31/565 A61K 31/567 A61P 15/00 A61P 19/00
Filing Date
2025-08-26
Application No.
19310386
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.